BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Results of Operations and Financial Condition

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On May 4, 2017, BioCryst Pharmaceuticals, Inc. issued a news
release announcing recent corporate developments and its
financial results for the quarter ended March 31, 2017, which
also referenced a conference call and webcast to discuss these
recent corporate developments and financial results. A copy of
the news release is furnished as Exhibit 99.1 hereto and is
incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by
reference under this Item 7.01 as if fully set forth herein.

The information furnished is not deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, is
not subject to the liabilities of that section and is not deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
99.1 Press release dated May 4, 2017 entitled BioCryst Reports
First Quarter 2017 Financial Results


About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session down -0.02 at 6.47 with 1,226,634 shares trading hands.

An ad to help with our costs